In this episode, Dr. Kumar reflects on the impact of uncertainty on rheumatology and the important role of the rheumatologist in providing clarity for patients. He also highlights important articles in the May issue for readers to note.
SAP-001 Promising for Refractory Gout
Initial findings from a phase 2b clinical trial demonstrate the safety and efficacy of three different daily doses of SAP-001 to lower the serum urate levels of patients with refractory gout.
Cilnidipine Receives Orphan Drug Status to Treat Systemic Sclerosis
Based on research showing improved signs and symptoms of systemic sclerosis in patients taking cilnidipine vs. placebo, the FDA granted orphan drug designation for the agent.
Nipocalimab Receives Breakthrough Therapy Status for Sjögren’s Disease
Nipocalimab, an investigational monoclonal antibody that blocks FcRn and reduces levels of circulating immunoglobulin G (IgG) antibodies, has received the FDA’s breakthrough therapy designation for the treatment of Sjögren’s disease.
Advocates for Arthritis 2025: United for the Future of Rheumatology Care
In visits to Congress members and staff, more than 120 ACR/ARP members and patients urged action to improve patient access to quality treatment. The meetings included discussions about the importance of research funding, ensuring adequate Medicare reimbursement, protecting Medicaid, and making PBMs more transparent and accountable. It’s not too late to amplify their message.
Incorporating Patient-Reported Outcomes into the Clinic
The ACR’s quality measures for care include gauging disease activity and functional status via patient-reported outcomes (PROs) and clinical assessments during routine care.1 But how do rheumatologists effectively incorporate PROs into a clinic visit? Christie Bartels, MD, MS, chief of the Division of Rheumatology and associate professor in the Department of Medicine, University of Wisconsin…
ACR Leaders Discuss Rheumatology Medications at Medicare Drug Price Negotiation Town Hall
On April 30, Rebecca Shepherd, MD, MBA, and Amanda Myers, MD, represented rheumatology in a live town hall on the Medicare Drug Price Negotiation Program, describing the benefits of apremilast and nintedanib for patients with rheumatic disease.
Can Stem Cell Transplantation Improve Survival Rates in Patients with Systemic Sclerosis?
Autologous hematopoietic stem cell transplantation (AHSCT) may improve the survival rate of patients with diffuse cutaneous systemic sclerosis (SSc), according to Georges et al. The single-arm clinical trial demonstrated the effectiveness of AHSCT and maintenance therapy. Researchers also identified potential risk factor of AHSCT in patients with low eGFR before transplantation.
FDA Approves Suzetrigine (VX-548), a Non-Opioid Analgesic
Based on research in post-surgery patients, the FDA approved suzetrigine, a non-opioid analgesic, for the treatment moderate to severe, acute pain in adults.
Advocates for Arthritis 2025: Preview of Key Issues
When ACR volunteer leaders, members and patient advocates head to Capitol Hill in May, they will urge members of Congress to protect Medicare and Medicaid against cuts, restore research funding and reform pharmacy benefit managers for better transparency and accountability.
- 1
- 2
- 3
- …
- 815
- Next Page »